FDA Inspection 1123814 — Xellia Pharmaceuticals ApS
The FDA completed an inspection of Xellia Pharmaceuticals ApS on October 25, 2019 in Copenhagen S. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- October 25, 2019
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Copenhagen S (Denmark)
Additional Details
Mutual Recognition Agreement (MRA)